Tratamiento farmacológico de la neoplasia corneal y conjuntival

López, Alberto; Blasco, Joaquín Borrás; Valero, M.C. Alvarado; Ruíz, A Navarro; Delgado, M. González; Toldos, J.J. Martínez

doi:10.1016/s1130-6343(05)73648-5

Cited by 4 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sample size was calculated using the Sample Size for Randomized Controlled Trials formula for which an alpha value of 0.05 and a power of 80% were chosen [11]. The standard deviation (σ) was obtained from a previous study [12] and the expected size of effect (d) was 1.73 months. A result of 7 subjects per group was obtained.…”

Section: Patients and Study Designmentioning

confidence: 99%

Safety and efficacy of topical interferon alpha 2B and mitomycin C for localized conjunctival intraepithelial neoplasia: long-term report of their pharmacological safety and efficacy

Alvarado-Castillo,

Santa Cruz-Pavlovich,

Gonzalez-Castillo

et al. 2023

BMC Ophthalmol

View full text Add to dashboard Cite

Purpose Ocular surface squamous neoplasia (OSSN) comprises a wide spectrum of squamous tumors, from which corneal/conjunctival intraepithelial neoplasia (CIN) is the most common one. The classic treatment is complete excision, but recurrence rates are high. Antineoplastic drugs such as mitomycin C (MMC) and interferon alpha 2b (IFNα2b) have been used as adjuvants or as primary treatment. To evaluate the efficacy and safety of topical IFNα2b and MMC in patients with CIN, a phase IIb double-blind clinical trial was performed. Methods Patients diagnosed with localized CIN were evaluated by slit lamp and impression cytology and were randomly given MMC 0.04% or INF2b (1 million IU/mL) 4 times daily until neoplasia resolution. Time of resolution and frequency of adverse effects were analyzed to determine the pharmacological efficacy and safety of both medications. Results Seventeen patients were included. Nine patients were treated with MMC and 8 with IFNα2b. All patients responded to treatment. The resolution time in days was 59.11 ± 24.02 in patients treated with MMC and 143.50 ± 47.181 in those treated with IFNα2b (p < 0.001). In the MMC group, one recurrence was reported (11%). There were no recurrences at 2 years of follow-up in the IFNα2b group. Regarding adverse effects, one or more mild adverse reaction occurred in 77% of patients managed with MMC and in 50% of patients managed with IFNα2b (p > 0.05). No serious adverse effects were reported. Conclusions Topical chemotherapy with MMC and IFNα2b demonstrate pharmacological safety and efficacy. Therefore, these drugs could be considered as primary therapies for localized CIN .

show abstract

Section: Patients and Study Designmentioning

confidence: 99%